Vitamin-C verdict may spell trouble ahead for multinational Chinese companies
On 14 March, a federal jury in New York found Chinese vitamin-C manufacturer Hebei Welcome Pharmaceutical Co and its parent, North China Pharmaceutical Group Corp, liable for agreeing with other Chinese manufacturers to fix prices in the vitamin-C market.
The jury awarded $54.1m (£35m) in damages to the plaintiffs — purchasers including US food and drink companies, packagers, wholesalers and distributors — an amount that was then trebled by the presiding judge to an award of $162.3m in accordance with federal antitrust laws. Three other Chinese manufacturers involved in the conspiracy reached settlements with the plaintiffs prior to the announcement of the verdict…
If you are registered and logged in to the site, click on the link below to read the rest of the Allen & Overy briefing. If not, please register or sign in with your details below.
News from Allen & Overy
News from The Lawyer
Briefings from Allen & Overy
Fondazione Enasarco v Lehman Brothers Finance is an important decision in the context of characterising which claims will fall as insolvency-derived claims.
Analysis from The Lawyer
‘Exotic’ investors and opportunities for legal work beyond M&A feature in The Lawyer’s high-level roundtable debate on south-east Europe
Why has Herbert Smith Freehills (HSF) decided to walk away from the Singapore qualifying foreign law practice (QFLP) scheme?